Corsair Gaming Inc vs Mesoblast Limited — how do they compare? Corsair Gaming Inc trades at $13.58 (market cap $1.42B), while Mesoblast Limited trades at $14.25 (market cap $1.75B). The key difference: Mesoblast Limited is the larger of the two by market cap, and Corsair Gaming Inc is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Corsair Gaming Inc for 25 Days and Mesoblast Limited for 15 Days on average.
| CRSR | MESO | |
|---|---|---|
Market Cap | $1.42B | $1.75B |
Volume | 1,160,938 | 239,027 |
Sector | Technology | Health |
52-Week High | $14.35 | $20.96 |
52-Week Low | $4.58 | $13.19 |
Typical Hold Time | 25 Days | 15 Days |
Enterprise Value | $1.41B | $1.83B |
Signals from Pluang's Aura AI — not financial advice
Corsair Gaming (CRSR) trades at $13.505, down 0.63% on the day, with a bullish technical signal and recent earnings beats driving positive momentum. The stock shows improving fundamentals with a projected net income margin of 2.53% for 2026, though current valuation metrics like a P/E of 42.23 appear elevated. Recent product launches and strategic acquisitions highlight growth initiatives in the gaming and creator segments.
The outlook is cautiously optimistic, supported by analyst buy ratings and strong cash flow projections for 2026. Key risks include competitive pressures and reliance on consumer discretionary spending, but institutional interest and earnings outperformance provide a foundation for potential upside if execution continues.
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Corsair Gaming Inc is engaged in the business of providing high-performance gear for gamers and content creators. The product portfolio includes Cases, Keyboards, Mice, Headsets, Power Supplies, Gaming Computers, Gaming Chairs, Mousepads, and other related products. The company operates in two segments namely, Gamer and Creator peripherals, which is the key revenue generating segment
Read more on CRSR →Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →